{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-24-002002","form_type":"8-K","ticker":"AXIM","cik":"0001514946","company_name":"AXIM BIOTECHNOLOGIES, INC.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.651147+00:00","generated_at":"2026-05-30T14:32:13.090739+00:00","sec_items":["5.01","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Change in control at AXIM Biotechnologies; CEO John Huemoeller dies, Catalina Valencia named President","bullets":["Kettner Investments acquires control via Series C Preferred Stock transfer from Juniper & Ivy and Medical Marijuana, Inc.","CEO/President John W. Huemoeller II died Oct 12 due to illness; board appointed Catalina Valencia as President on Oct 9.","Valencia also appointed Series C Director to fill vacancy from Huemoeller's death; she previously founded Sapphire Biotech.","Series C stock transferred from Juniper to MJNA to satisfy $515K note, then to Kettner to waive $1.09M notes plus $66K interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-24-002002","json":"https://secwatch.observer/filing/0001096906-24-002002.json","markdown":"https://secwatch.observer/filing/0001096906-24-002002.md","text":"https://secwatch.observer/filing/0001096906-24-002002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/axim-20241009.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:32:13.090739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bf2ce4ae0","claim":"Catalina Valencia was appointed as Series C Director at AXIM BIOTECHNOLOGIES, INC..","evidence_excerpt":"effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Series C Director"}],"fact_type":"executive_change"},{"claim_id":"74b9f1037d","claim":"John W. Huemoeller II departed as President and CEO at AXIM BIOTECHNOLOGIES, INC..","evidence_excerpt":"Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"unable to serve"},{"label":"Role","value":"President and CEO"}],"fact_type":"executive_change"},{"claim_id":"9bbfbeff02","claim":"John W. Huemoeller II departed as Series C Director at AXIM BIOTECHNOLOGIES, INC..","evidence_excerpt":"On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"died"},{"label":"Role","value":"Series C Director"}],"fact_type":"executive_change"},{"claim_id":"dbf8897511","claim":"Catalina Valencia was appointed as President at AXIM BIOTECHNOLOGIES, INC..","evidence_excerpt":"on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}